Liver transplantation (LT) is a successful treatment for both acute liver failure and end-stage liver disease. The number of women of reproductive age undergoing LT is increasing. Pregnancy outcomes are favorable, but there is still a lack of prognostic markers. We aimed to identify factors predictive of adverse pregnancy outcomes in LT recipients. An analysis of all pregnancies occurring in LT recipients from 1989 to 2016 at King's College Hospital was performed. Clinical data of 162 conceptions in 93 women were reviewed. Descriptive and regression analyses were done to examine associations between laboratory markers and hepatological scores with pregnancy outcomes of live birth and preterm birth. Median age at LT was 23 years (range, 1-41 years), with a median age at conception of 30 years (range, 18-47 years). The live birth rate was 75% (n 5 121). Of live births, 35% (n 5 39/110 available) were delivered preterm. Preconception creatinine levels were higher in patients who had a preterm birth (85 versus 74 lmol/ L; P 5 0.008), with a preconception estimated glomerular filtration rate (eGFR) <90 mL/minute significantly associated with preterm delivery (P 5 0.04). Progressive decline in eGFR predicted outcome, with gestational length declining with increasing chronic kidney disease (CKD) stage: CKD 0-1 5 39 weeks (median), CKD 2 5 37 weeks, and CKD 3 5 35 weeks. The risk of preterm birth was greatest in women with an eGFR <60 mL/minute (P 5 0.004). Moreover, hypertension-related complications during pregnancy, such as gestational hypertension, preeclampsia, or eclampsia, were also associated with prematurity (P 5 0.01). Women taking steroid-based immunosuppression had an increased risk of infection during pregnancy or postpartum (15% versus 4%; P 5 0.02). In conclusion, although the majority of women have a successful pregnancy outcome after LT, preconception renal function predicts pregnancy outcome and steroids increase risk of infection during pregnancy or postpartum.
Since the first successful pregnancy in a liver transplantation (LT) recipient was reported in 1978, (1) survival following LT has steadily increased. (2, 3) Indeed, a center recently reported a 20-year survival rate of 53%. (4) Moreover, success of LT has led to an increase in the number of women of reproductive age (18-49 years) undergoing LT. In the United States, 22% of women are of reproductive age undergoing transplant, while survival of childhood LT recipients has also increased. (5) Data from the United Kingdom largely replicate these trends. (6) Amenorrhea and infertility are well recognized in patients with chronic liver disease. This is caused by disruption of the hypothalamic-pituitary-gonadal axis. However, menstruation and fertility can be restored within 10 months of successful LT. (7, 8) For young women, there is an expectation of returning to a normal quality of life after LT, including the ability to have children. (9) Pregnancy outcomes following LT including previous reports from our own center have been shown to be favorable, but with an increased risk of premature birth, intrauterine growth restriction, and graft dysfunction. (10) (11) (12) (13) (14) The dominant prepregnancy advice was to recommend deferral of pregnancy to a time period >1 year following transplant. However, the influence of biochemical parameters after LT on pregnancy outcomes has not yet been completely evaluated. We aimed to identify new prognostic markers for both maternal and fetal outcomes for pregnancies in LT recipients.
Patients and Methods
We conducted a retrospective analysis of all pregnancies in LT recipients between 1989 and 2016 at King's College Hospital (KCH). Patients were identified from a prospectively collated liver database using the search terms pregnancy, LT, miscarriage, abortion, and termination. The clinical records of all patients were reviewed and data were collected including indication for LT, age at transplant, age at conception, interval between LT and pregnancy, and immunosuppressive therapy. Data on maternal and fetal outcomes were also obtained, including gestational age, mode of delivery, as well as complications such as gestational hypertension, preeclampsia, eclampsia, gestational diabetes, and infection.
Where medical records stated "term" gestations (n 5 6), an arbitrary decision to code these pregnancies as 39-week gestation was undertaken for further statistical analysis. Liver-related complications including acute cellular rejection (ACR) and graft loss were also recorded. Laboratory results within 6 months before conception were collected (if multiple were available, then the results closest to conception were collected), including hemoglobin, platelet count, international normalized ratio (INR), sodium, creatinine, albumin, bilirubin, and aspartate aminotransferase (AST) levels. Hepatological scoring systems exist in clinical practice for assessing the severity of cirrhosis and the degree of fibrosis. Because of the lack of prognostic scoring systems in the post-LT setting, we assessed the utility of these noninvasive scores to prognosticate pregnancy outcomes in LT recipients. Model for End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease-sodium (MELD-Na), United Kingdom End-Stage Liver Disease (UKELD), albumin-bilirubin grade (ALBI), and aspartate aminotransferase-to-platelet ratio index (APRI) were calculated according to published formulas. (15) (16) (17) (18) (19) The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study equation. (20) For stratification purposes, eGFR was classified into chronic kidney disease (CKD) stage according to the National Kidney Foundation guidelines. (21) In patients with stable graft function, we advise patients to maintain their immunosuppressive regimen throughout pregnancy. During the cyclosporine era, some patients were advised to reduce their immunosuppressive regimen. All patients on mycophenolate mofetil (MMF) previously received advice against pregnancy due to its risks of teratogenicity. (22) However, should unplanned pregnancies occur on MMF, we advised discontinuation or switching immunosuppressive regimen and consideration for termination, depending on gestation.
STATISTICAL ANALYSIS
Data are presented as median and interquartile range (IQR) for numerical values, unless stated otherwise. Fisher's exact or chi-square tests and Mann-Whitney U tests were used to compare groups of categorical and continuous variables, respectively. Statistical significance was defined as P value < 0.05. Live birth gestations plotted as survival curves were estimated by the Kaplan-Meier method and compared with the logrank test. All analyses were performed using SPSS, version 24 (IBM, Chicago, IL) and GraphPad Prism, version 7 (GraphPad Software, La Jolla, CA). Factors found significant on univariate analysis (P < 0.05) were then included in the stepwise multiple logistic regression analysis to identify independent factors associated with preterm birth. All data were anonymized before analysis, and the use was approved by the research ethics committee of KCH.
Results

PATIENT DEMOGRAPHICS
A total of 162 conceptions occurred in 93 women between 1989 and 2017. The median age at LT was 23 years (range, 1-41 years), with a median age at conception of 30 years (range, 18-47 years). Indications for LT are summarized in Table 1 . The ethnicity of the women was Caucasian in 74 (80%), African/AfroCaribbean in 6 (7%), South Asian in 6 (7%), East Asian in 3 (3%), and other in 4 (4%). Overall, 48 women had 1 conception, whereas 45 had multiple pregnancies: 30 had 2 conceptions, 10 had 3 conceptions, 3 had 4 conceptions, and 2 had 6 conceptions. Patient demographics and pregnancy outcomes are summarized in Table 2 .
Over the 3 decades examined, the number of women of reproductive age (18- 
MATERNAL OUTCOMES
There was no pregnancy-related maternal death. ACR occurred during pregnancy in 11 (12%) women, whereas another 8 (9%) developed ACR after delivery. Graft rejection was defined either histologically, or where biopsy is not available, on the basis of biochemical and clinical evaluation. ACR episodes were treated either with augmentation of their baseline immunosuppression and oral prednisolone or 3 daily doses of 1000 mg methylprednisolone, followed by a reducing course of prednisolone. No episode of postpartum ACR resulted in graft loss. Patients with an episode of rejection, either before or during pregnancy, did not have increased risk of adverse pregnancy outcomes of nonlive birth or prematurity (P 5 0.57 and 0.18, respectively). ACR was significantly more common in women who conceived within 1 year of LT (46% versus 13%; P 5 0.03).
Twelve women developed an episode of either microbiologically confirmed or antibiotic-treated NOTE: Data are given as n (%). *Alpha 1 antitrypsin deficiency, congenital hepatic fibrosis, Crigler-Najjar syndrome, epithelioid hemangioendothelioma, fibrolamellar liver tumor, glycogen storage disease, benign liver tumors. NOTE: Data are given as n (%) and median (IQR) unless otherwise noted.
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infection during pregnancy or in the postpartum period. Patients taking steroid-based immunosuppression were significantly more likely to develop infection (7/48, 15%, versus 5/114, 4%; P 5 0.02; Fig. 2 ). Six women required intravenous antibiotics for sepsis (streptococcal bacteremia, n 5 1; pneumonia, n 5 1; urinary tract, n 5 1; liver abscesses, n 5 2; and unknown source, n 5 1), whereas the other 5 women received oral antibiotics (source of infections include chest, n 5 3; finger, n 5 1; and urinary tract, n 5 1). One patient developed a parvovirus infection. All infections occurred either in the third trimester or in the postpartum period.
Hypertensive complications occurred at a greater frequency than that reported in the UK population, including gestational hypertension (10% versus 6%), preeclampsia (12% versus 0.5%), and eclampsia (2% versus 0.04%). (23) Among the pregnancies complicated with preeclampsia, 4/20 (20%) occurred in women with preexisting hypertension. Preexisting hypertension increases the risk of preeclampsia compared with those without hypertension prepregnancy (16% versus 11%; P 5 0.03). Women with any hypertensive complication during pregnancy have an increased risk of preterm birth (median gestation, 35 versus 38 weeks; P 5 0.01).
Three patients developed evidence of graft decompensation in the form of ascites, all of which recovered following delivery. All patients had a preconception APRI score of >1.5. The first woman had evidence of persistent portal hypertension after LT and developed ascites during pregnancy resulting in a stillbirth at 20 weeks gestation. The second woman had established cirrhosis secondary to recurrence hepatitis C virus infection and developed ascites following a miscarriage at 4 weeks. The final woman had established graft dysfunction due to chronic rejection. She became jaundiced and encephalopathic in the second trimester, and she had an emergency caesarean section following spontaneous rupture of membranes at 28 weeks gestation. Remarkably, her liver function improved following the delivery of the baby.
LONGTERM MATERNAL OUTCOMES
The median follow-up for the 93 women was 16 years (1-46 years) after delivery. Eleven women died during the follow-up period, and none died within 12 months postpartum. Two of these women had undergone retransplantation for chronic rejection, at 13 and 16 years postpartum. The median duration from delivery to death was 66 months (15-192 months) . Eight women died from multiorgan failure and sepsis, 1 each died from lymphoma, metastatic colorectal carcinoma, and restenosis of the inferior vena cava with subsequent graft failure. Eight other women underwent retransplantation at a median time of 42 months postpartum (range, 18-192 months). The causes of graft failure were chronic rejection (n 5 5, including 2 who died), recurrent disease (n 5 3), portal hypertension secondary to nodular regenerative hyperplasia (n 5 1), and late hepatic artery thrombosis (n 5 1). In all cases, graft loss was thought to be unrelated to pregnancy.
FETAL OUTCOMES
There were 121 from 162 conceptions that resulted in a live birth (75%). There were 10 (6%) elective terminations of pregnancy, 29 (18%) miscarriages (<20 weeks gestation), and 2 (1%) stillbirths (20 weeks gestation) at gestational weeks 20 and 26. The median gestation was 36 weeks (range, 4-42 weeks). Of the live births, there were exact gestation data available for 110 pregnancies, with 71 (65%) reaching term (37 weeks). The mode of delivery was vaginal in 61 (55%) pregnancies and caesarean in 49 (45%) pregnancies. Complete preconception maternal blood results were available for 104 patients. Table 3 summarizes the demographics of premature births and pregnancies reaching term.
The indication for LT, maternal age (at LT or conception), time from LT to conception, intrapregnancy or postpartum rejection (n 5 19, 12%), preconception bilirubin, platelet count, AST, and preconception 
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tacrolimus level did not correlate with preterm delivery or fetal outcomes. Higher preconception MELD score was associated with prematurity (8 versus 7; P 5 0.01), whereas MELD-Na, UKELD, ALBI, and APRI did not correlate with adverse pregnancy outcomes. Six (4%) babies required ward-based medical management after delivery, and 10 (6%) babies required admission to the Special Care Baby Unit or Neonatal Intensive Care Unit. Two pregnancies resulted from in vitro fertilization (1 was a twin pregnancy), and both had successful deliveries at 34 and 36 weeks gestation, respectively. A comparison was also done on pregnancies resulting in a live birth, with those resulting in a miscarriage. There was no significant difference in the patient characteristics between the 2 groups (see Supporting Table  1 ). Only MMF exposure in early pregnancy was significantly associated with miscarriage as discussed in the next section. Other factors such as maternal age, indication for LT, time from LT to conception, or preconception bilirubin, platelet count, AST, and creatinine were not significantly different between the 2 groups.
IMMUNOSUPPRESSION
The majority of patients were maintained on calcineurin inhibitor (CNI)-based immunosuppressants (tacrolimus, 78%; cyclosporine, 17%). All patients who were maintained on cyclosporine-based immunosuppressive regimen underwent transplantation before the year 2000. Eight (5%) patients were on azathioprine as the primary immunosuppressive agent and underwent transplantation before 1997, whereas in 5 (3%) patients, MMF was used in conjunction with tacrolimus.
One patient was on sirolimus-based immunosuppression in combination with tacrolimus and prednisolone for augmented immunosuppressive regimen following an episode of rejection at the time of conception. She continued this regimen throughout pregnancy and delivered via caesarean section at 37 weeks gestation. The baby was born without structural malformations.
The prescribed CNI immunosuppression regimen had no impact on pregnancy outcome except for 5 pregnancies exposed to MMF. These were all unplanned pregnancies, with 1 live birth, 1 elective termination, and 3 miscarriages. All women discontinued MMF. The termination was performed at 10 weeks gestation, whereas the miscarriages occurred at 8, 9, and 11 weeks gestations. The rate of miscarriage was significantly higher than pregnancies not exposed to MMF (50% versus 16%; P 5 0.04). The only live birth was delivered via caesarean section at 28 weeks gestation and required special medical care but had no congenital abnormalities.
TIMING OF PREGNANCY
Conceptions occurring within 12 months of LT had no impact on the likelihood of live birth (P 5 0.76), but there was an increased risk of prematurity compared with those patients who conceived more than 1 year after LT (71% versus 50%; P 5 0.16). This was statistically significant only when live births were considered (64% versus 32%; P 5 0.045; Fig. 3 ). Comparing the laboratory and clinical parameters in women who conceived within 12 months of LT to those who conceived after 12 months, only age at LT and serum sodium were significantly different. The median age at LT for conceptions within 12 months of LT was 29 years (range, 19-41 years) compared with 23 years (range, 1-41 years) for conceptions occurring 1 year after LT (P 5 0.03). Serum sodium for conceptions within 12 months of LT was 140 mmol/L compared with 141 mmol/L (P 5 0.04).
IMPACT OF RENAL DYSFUNCTION ON PREGNANCY OUTCOME
Median preconception eGFR was lower in patients who had a preterm birth (83 versus 70 mL/minute; P 5 0.02). Preconception eGFR < 90 mL/minute (CKD 2) was significantly associated with preterm delivery (P 5 0.04), and the effect was more pronounced when analyzing those with preconception eGFR < 60mL/minute or CKD stage 3 (P 5 0.004). Interestingly, we observed that the median gestation decreased with each increment in CKD stage: CKD 0-1 5 39 weeks; CKD 2 5 37 weeks; and CKD 3 5 35 weeks (P 5 0.003). Only 33% of pregnancies in patients with CKD stage 3 reached term, compared with 69% in CKD stage 2 (eGFR 60-90 mL/minute) and 79% in CKD stage 0-1 (eGFR 90 mL/minute; P 5 0.01; Fig. 4 ). Women with impaired renal function were screened for a primary renal pathology by ascertaining relevant history, performing urine dipstick, myeloma screen, autoimmune serology, and renal tract imaging as necessary. All cases of renal impairment in these women were likely multifactorial, with CNI toxicity being the predominant cause.
MULTIVARIATE ANALYSIS OF PREDICTORS OF PREGNANCY OUTCOME
As described above and in Table 3 , univariate analysis was performed on the following variables including preconception serum tests, age at conception, age at LT, conception within 1 year of LT, and "any hypertensive-related complication during pregnancy." A standard multiple logistic regression was performed to determine the relationship between 3 identified predictor variables of term birth (37 weeks) from univariate analysis:
1. Preconception eGFR. 2. Conception within 1 year of LT. 3. Hypertensive-related complication during pregnancy.
Preconception eGFR and any episode of a hypertensive-related complication were associated with preterm birth in a multivariate model (P 5 0.036 and 0.021, respectively). Conception within 1 year of LT, however, did not reach significance (P 5 0.661). The results are summarized in Table 4 .
Discussion
Our results show that the number of live births is increasing in parallel to the number of women of reproductive age undergoing LT. Moreover, the live birth rate has also increased significantly over the last 3 decades. We described how preterm birth is associated with worsening renal function. Additionally, a steroidbased immunosuppressive regimen increases the risk of an infection during pregnancy or the postpartum period.
The number of pregnancies in LT recipients has been rising steadily over the last few decades. Pregnancy outcomes in a meta-analysis and a number of case series, including our own unit, are favorable, but inherent fetal and maternal risks remain. (10) (11) (12) (13) (24) (25) (26) (27) These women will expect and require extensive counseling regarding contraception and pregnancy from their transplant physicians and obstetrics team. Interestingly, we show that live birth rates over the last 3 decades have improved significantly, likely reflecting improvements in hepatological and obstetric care.
There is a lack of prognostic markers for pregnancy outcomes in LT recipients. Previous studies have shown that pregnancies occurring within 12 months of transplantation have an increased risk of an episode of ACR during pregnancy or immediately postpartum. (11, 24, 27, 28) We have shown that conception within the first year after LT is associated with an increased risk of prematurity. However, this did not reach significance in a multivariate model. Moreover, preconception renal function seemed to be an important predictor of gestation in LT recipients. The majority of pregnant women (79%) with CKD stage 0/1 had a term pregnancy compared with only 33% of those with CKD stage 3. This parallels data of pregnancy outcomes in patients with CKD and renal transplants. The association between prematurity and preconception renal function was described in a United Kingdom national cohort study of renal transplant recipients and a report from the UK Transplant Pregnancy Registry. (29, 30) In addition, a meta-analysis of 23 studies, including over 1500 pregnancies in women with CKD, showed an increased risk of premature delivery, preeclampsia, low birth weight, and failed pregnancy with increasing CKD stage. (31) Furthermore, an observational study of 504 pregnant women with CKD showed a stepwise worsening of pregnancy outcomes with advancing CKD stage. (32) The risk was independent of significant proteinuria, for which data were not available for our study.
It seems clear that impaired renal function confers an increased risk of preterm birth in LT recipients. Nevertheless, women with a normal renal function before pregnancy or eGFR 90 mL/minute still have a significantly higher rate of prematurity compared with the general population (21% versus 7%). (33) This suggests that prematurity risk following LT is likely influenced by additional factors. Furthermore, the cause of renal impairment in LT recipients is usually multifactorial. CNIs play a significant role, and the safest immunosuppressive regimen that preserves renal function remains to be established. Therefore, the ideal immunosuppressive regimen needs to be individualized for each LT recipient to optimize both graft and renal function.
Hypertension and hypertension-related complications during pregnancy are known to adversely affect pregnancy outcomes. (32, 34) We have shown that hypertension and related complications are more common in pregnant LT recipients. This mirrors the published data of kidney transplant recipients, which showed that a history of chronic hypertension increases the risk of preeclampsia. The development of an episode of hypertension-related complications, such as gestational hypertension, preeclampsia, or eclampsia was significantly associated with a risk of prematurity in our study. This was shown to be an independent marker of impaired renal function on multiple logistic regression analysis.
Our data also showed an increased risk of infection during pregnancy or immediately after delivery in women on steroid-based immunosuppressive regimen. Prednisolone is usually used in combination with a CNI immunosuppressant in the early posttransplant period and as part of the longterm immunosuppressive regimen for women transplanted for autoimmune liver disease. A recent large observational cohort study of patients with autoimmune inflammatory conditions identified the use of high-dose steroids as an independent risk factor for serious infections in pregnancy. (35) The episodes of infection observed in this study occurred either during the third trimester or the postpartum period. This could reflect a vulnerable period for risk of infection in women on steroid-based immunosuppression. Notably, the daily prednisolone dosage used in our patient cohort was relatively small (5-10 mg) compared with the above study. However, this reflects the data in patients with rheumatoid arthritis where any glucocorticoid exposure was associated with an increased risk of infection. (36) It is important that clinicians have an increased recognition of such complications. NOTE: Data calculated using the following predictors: (1) eGFR in mL/minute, as calculated using the MDRD equation; (2) conception within 1 year of LT; and (3) an episode of hypertension-related complication, such as gestational hypertension, preeclampsia, or eclampsia.
Three women developed evidence of liver decompensation during pregnancy or soon after the end of pregnancy. Two of these pregnancies failed, and 1 baby was born prematurely at 28 weeks. All 3 women had either persistent portal hypertension or established graft dysfunction before conception. Therefore, perhaps unsurprisingly, the stage of liver disease prior to conception is likely to be an important factor for a successful pregnancy. Overall, however, pregnancy following LT did not appear to adversely affect graft or patient survival. Our results reflect previous studies, which demonstrated only a small proportion of women experiencing graft loss within 2 years of delivery. (10, 28) A limitation of this study is its retrospective nature and that the inclusion of pregnancies relied on selfreporting from patients. However, LT recipients are followed up regularly and have high engagement with our clinical services. We felt that the likelihood of having missed pregnancies was low. Notwithstanding that, the recording and extent of pregnancy information, eg, birth weight, were variable, and the use of a data collection proforma and pregnancy registries will help standardize data capture in the future.
In conclusion, there are currently limited prognostic markers predicting outcomes in LT recipients wishing to get pregnant. We have shown for the first time that preconception renal function is a useful marker to prognosticate pregnancy outcomes in women following LT. The presence of chronic hypertension or hypertensive complications during pregnancy was associated with an increased risk of preterm birth. Moreover, the use of steroid-based immunosuppressive regimens increased the risk of infection during pregnancy and the peripartum period. Our results will help to tailor pregnancy counseling and care for women after LT. Because of the complexity of such pregnancies, it is recommended that all pregnancies in women after LT are managed by a multidisciplinary team including transplant clinicians and specialist obstetricians.
